SCHEMBL21714141

SCHEMBL21714141

O=C(O)N1CCCCC1CNS(=O)(=O)c1cccnc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.45
TSHR P16473 2/20 0.45
DPP4 P27487 5/20 0.42
ALDH1A1 P00352 4/20 0.41
MAPT P10636 2/20 0.41
DPP8 Q6V1X1 2/20 0.41
DPP9 Q86TI2 2/20 0.41
DPP7 Q9UHL4 2/20 0.41
POLB P06746 1/20 0.41
RECQL P46063 1/20 0.41
HCRTR1 O43613 1/20 0.40
HCRTR2 O43614 1/20 0.40
SLC22A12 Q96S37 2/20 0.39
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CNR2 P34972 1/20 0.39
ACLY P53396 1/20 0.39
ALOX15 P16050 1/20 0.38
CTSL P07711 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21714012 0.97 DPP4 (0.45) HPGDTSHRDPP4ALDH1A1MAPT
SCHEMBL21713810 0.92 HPGD (0.42) HPGDTSHRDPP4ALDH1A1MAPT
SCHEMBL21714047 0.86 KDM1A (0.47) HPGDTSHRDPP4ALDH1A1MAPT
SCHEMBL29819176 0.86 KDM1A (0.47) HPGDTSHRDPP4ALDH1A1MAPT
SCHEMBL21713456 0.83 CNR2 (0.42) HPGDTSHRDPP4ALDH1A1MAPT
SCHEMBL21713889 0.83 DPP4 (0.42) HPGDTSHRDPP4ALDH1A1DPP8
SCHEMBL21713985 0.82 DPP4 (0.38) HPGDTSHRDPP4DPP8DPP9
SCHEMBL21713313 0.82 HCRTR1 (0.43) HPGDTSHRDPP4ALDH1A1MAPT
SCHEMBL21714418 0.81 SLC22A12 (0.41) HPGDDPP4ALDH1A1DPP8DPP9
SCHEMBL21713306 0.81 HPGD (0.39) HPGDTSHRDPP4ALDH1A1DPP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4364804-A2 INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION Janssen Pharmaceutica NV (BE) 2024-05-08 EP disclosed
US-11897900-B2 Inhibitors of KEAP1-Nrf2 protein-protein interaction JANSSEN PHARMACEUTICA NV (BE) 2024-02-13 US disclosed
EP-3833662-B1 INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2024-01-17 EP disclosed
EP-3833662-A2 INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION Janssen Pharmaceutica N.V. (BE) 2021-06-16 EP disclosed
US-10947252-B2 Inhibitors of KEAP1-Nrf2 protein-protein interaction JANSSEN PHARMACEUTICA NV (BE) 2021-03-16 US disclosed
WO-2020041169-A2 INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2020-02-27 WO disclosed
US-20200055874-A1 INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2020-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11897900-B2 Inhibitors of KEAP1-Nrf2 protein-protein interaction KEAP1, NFE2L2, HMOX1 HPGD 152/4885TSHR 4787/4885DPP4 4374/4885
US-20200055874-A1 INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION KEAP1, NFE2L2, HMOX1 HPGD 152/4885TSHR 4787/4885DPP4 4374/4885
US-10947252-B2 Inhibitors of KEAP1-Nrf2 protein-protein interaction KEAP1, NFE2L2, HMOX1 HPGD 152/4885TSHR 4787/4885DPP4 4374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.